ObjectiveTo explore the mechanism of Yishen Qubi Tongluo Formula （益肾祛痹通络方， YQTF） in the treatment of rheumatoid arthritis（RA）. MethodsNetwork pharmacology was employed to retrieve and screen the active components and potential targets of YQTF as well as RA-related targets using databases including TCMSP， BATMAN， ETCM and GEO. The intersection of targets related to active components and RA-related targets was identified， and a protein-protein interaction （PPI） network was constructed. Gene Ontology （GO） functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes （KEGG） pathway enrichment analysis were performed， and a drug-active component-common target network of YQTF in the treatment of RA was established. The core components of YQTF were molecularly docked with key targets. Human rheumatoid arthritis synovial fibroblast cell line MH7A was divided into blank group， model group， methotrexate group and YQTF group. The blank group was cultured with 10% fetal bovine serum， while the other three groups were stimulated with 10 μg/L of recombinant human tumor necrosis factor-α （TNF-α） for 24 h to establish the RA cell model. On this basis， the methotrexate group was treated with methotrexate suspension at a concentration of 20 μmol/L， and the YQTF group was treated with 10% YQTF-medicated serum. After 48 h of intervention， the levels of TNF-α and interleukin-17A（IL-17A）contents in cell supernatants were detected by enzyme-linked immunosorbent assay （ELISA）， and mRNA expressions of phosphatidylinositol 3-kinase（PI3K）， protein kinase B（AKT） and mammalian target of rapamycin（mTOR） were detected by real-time quantitative polymerase chain reaction （RT-qPCR）. ResultsNetwork pharmacological analysis identified 209 active components and 583 potential target genes of YQTF， as well as 818 RA-related targets. A total of 29 common targets were obtained from the intersection of drug-related targets and RA-related targets. Quercetin，β-sitosterol， kaempferol， stigmasterol and luteolin were the core active components of YQTF for the treatment of RA， while matrix metalloproteinase-9 （MMP9）， prostaglandin-endoperoxide synthase 2 （PTGS2）， Toll-like receptor 4 （TLR4）， tumor protein p53 （TP53） and transcription factor AP-1 subunit JUN were the key targets. The GO and KEGG pathway enrichment analysis showed that the involved biological processes and pathways were mainly associated with antioxidant responses， PI3K-AKT signaling pathway and Toll-like receptor （TLR） signaling pathway. Molecular docking results showed that MMP9 and PTGS2 exhibited high binding affinities with quercetin， β-sitosterol， kaempferol， stigmasterol and luteolin； TLR4 exhibited high binding activities with β-sitosterol， stigmasterol and luteolin； and TP53 showed high binding affinity with luteolin. The results of cell experiments showed that compared with the control group， the contents of TNF-α and IL-17A as well as the mRNA expressions of AKT and mTOR in the model group significantly increased （P＜0.05 or P＜0.01）. Compared with the model group， all the above indicators significantly decreased in the YQTF group， while the contents of TNF-α and the mRNA expression of AKT significantly decreased in the methotrexate group （P＜0.05 or P＜0.01）. ConclusionThe mechanism of YQTF in the treatment of RA may be associated with reducing inflammatory cytokine secretion and inhibiting the activation of the PI3K-AKT-mTOR signaling pathway.

N6-methyladenosine(m6A)is recognized as the most prevalent mRNA modification in mammals, intricately involved in a multitude of processes pertaining to mRNA metabolism, encompassing RNA transcription, translation, and degradation. It plays a pivotal role in various physiological functions. Under the coordinated actions of methyltransferases, demethylases, and m6A-binding proteins, m6A modifications undergo reversible changes to fulfill their diverse molecular functions.Methyltransferase-like 3(METTL3), as the core catalytic subunit of methyltransferases and the most extensively studied methyltransferase, holds a central position in m6A modification. In recent years, it has been found that METTL3-mediated m6A modification is involved in the occurrence and development of various ocular diseases, such as ocular surface diseases, glaucoma, cataract, retinal diseases, and ocular tumors, by affecting the expression of inflammatory factors and thus regulating the inflammatory response, and by regulating various pathways that affect the proliferation of cells and oxidative stress. In this paper, we comprehensively review the mechanisms under the role of METTL3 in ocular diseases, offering novel insights and perspectives for the prevention and management of these conditions.

Objective To investigate the association of insulin resistance(IR)and its related indices,including triacylglycerol-glucose(TyG)index and metabolic score of insulin resistance(Mets-IR),with the occurrence of early neurological deterioration(END)in patients with branch atheromatous disease(BAD),and develop a risk prediction model based on these factors.Methods A total of 189 BAD patients were consecutively recruited from the Department of Neurology of the Second Affiliated Hospital of Zhengzhou University between March 2020 and August 2024.Based on the occurrence of END within 7 d after admission,the participants were stratified into END(75 cases)and non-END(114 cases)groups.Demographic characteristics,clinical parameters,TyG index and Mets-IR values were systematically collected and analyzed.Multivariate logistic regression analysis was performed to identify independent risk factors for END in BAD-related stroke.Receiver operating characteristic curve(ROC)analysis was subsequently conducted to evaluate the predictive performance of significant variables,followed by construction of a nomogram prediction model.Results The END group exhibited significantly elevated fasting blood glucose[6.47(5.74,7.86)mmol/L vs 5.83(5.14,6.70)mmol/L]and triacylglycerol[1.65(1.21,2.04)mmol/L vs 1.27(0.99,1.57)mmol/L]levels,higher body mass index[25.02(23.88,26.67)kg/m2 vs 23.71(22.66,25.27)kg/m2]and TyG index(9.03±0.41 vs 8.71±0.45),and increased Mets-IR(39.98±4.23 vs 36.85±4.38)and NIHSS score[5.00(3.00,7.00)vs 3.00(2.00,5.00)]at admission when compared with the non-END group(P＜0.05).Multivariate logistic regression analysis showed that high TyG index(OR=3.751,95％CI:1.592-9.202,P＜0.01),Mets-IR(OR=1.146,95％CI:1.049-1.252,P＜0.01),and NIHSS score at admission(OR=1.279,95％CI:1.128-1.451,P＜0.01)were risk factors for the occurrence of END in BAD patients(P＜0.05).ROC curve indicated that the AUC value of TyG index,Mets-IR,and NIHSS score at admission in predicting END occurrence was 0.698(95％CI:0.623-0.774,P＜0.01),0.698(95％CI:0.620-0.775,P＜0.01),and 0.666(95％CI:0.586-0.745,P＜0.01),respectively.The nomogram prediction model based on these factors demonstrated significant clinical benefits by decision curve analysis and goodness of fit in internal calibration analysis.Conclusion IR shows significant association with END in BAD patients.The IR related indices,TyG index and Mets-IR,have certain predictive efficiency for occurrence and progression of END.

An imbalance between oxidative and antioxidant defense mechanisms in the body triggers oxidative stress,which causes a series of damages to the body,tissues and cells.The eye is particularly susceptible to oxidative stress due to its prolonged exposure to light and its anatomical characteristics of high metabolism and oxygen consumption.In addi-tion,inflammation,aging,genetic and environmental factors can promote the production of reactive oxygen species and weaken antioxidant defense mechanisms,which are all risk factors for oxidative stress that can lead to a variety of ocular diseases.The aim of this paper is to review the mechanisms of oxidative stress in ocular diseases such as ocular surface diseases,glaucoma,cataract,and retinopathy.At the same time,the potential therapeutic approaches to these diseases by regulating oxidative stress are discussed,so as to provide new ideas and directions for the diagnosis and treatment of ocular diseases.

Objective:To evaluate the efficacy of defocus incorporated multiple segments (DIMS) on spherical equivalent (SE) and axial length (AL) in myopic children.Methods:Clinical studies on the progress of DIMS lens intervention in myopia reported in CNKI, Wanfang Data, VIP, China Biomedical Literature Database, PubMed, Embase, Cochrane Library, and Web of Science from the establishment of the database to June 2023 were searched.The experimental group and control group used DIMS lens and single vision lens (SVL) for intervention, respectively.Two researchers independently conducted the literature search, screening and data extraction based on the inclusion and exclusion criteria.Literature quality and risk of bias were evaluated in accordance with the requirements of the Cochrane Manual.Meta-analysis was performed using Revman 5.4 software.Results:A total of 7 clinical studies using DIMS lenses to intervene in the development of myopia were included .Seven studies provided complete SE data for analysis, with sample sizes of 1 164 eyes and 1 140 eyes for the DIMS group and SVL group, respectively.Five studies provided complete AL data for analysis, with sample sizes of 339 eyes and 315 eyes for the DIMS group and SVL group, respectively.There were statistically significant differences in SE and AL between DIMS group and SVL group (SE: WMD=0.40, 95% CI: 0.32-0.47, P<0.001; AL: WMD=-0.14, 95% CI: -0.17--0.11, P<0.001).DIMS lens could effectively delay SE progression and AL growth in myopic patients. Conclusions:DIMS lenses could delay the increase of SE and AL to a certain extent.

Objective:To evaluate the efficacy of defocus incorporated multiple segments (DIMS) on spherical equivalent (SE) and axial length (AL) in myopic children.Methods:Clinical studies on the progress of DIMS lens intervention in myopia reported in CNKI, Wanfang Data, VIP, China Biomedical Literature Database, PubMed, Embase, Cochrane Library, and Web of Science from the establishment of the database to June 2023 were searched.The experimental group and control group used DIMS lens and single vision lens (SVL) for intervention, respectively.Two researchers independently conducted the literature search, screening and data extraction based on the inclusion and exclusion criteria.Literature quality and risk of bias were evaluated in accordance with the requirements of the Cochrane Manual.Meta-analysis was performed using Revman 5.4 software.Results:A total of 7 clinical studies using DIMS lenses to intervene in the development of myopia were included .Seven studies provided complete SE data for analysis, with sample sizes of 1 164 eyes and 1 140 eyes for the DIMS group and SVL group, respectively.Five studies provided complete AL data for analysis, with sample sizes of 339 eyes and 315 eyes for the DIMS group and SVL group, respectively.There were statistically significant differences in SE and AL between DIMS group and SVL group (SE: WMD=0.40, 95% CI: 0.32-0.47, P<0.001; AL: WMD=-0.14, 95% CI: -0.17--0.11, P<0.001).DIMS lens could effectively delay SE progression and AL growth in myopic patients. Conclusions:DIMS lenses could delay the increase of SE and AL to a certain extent.

An imbalance between oxidative and antioxidant defense mechanisms in the body triggers oxidative stress,which causes a series of damages to the body,tissues and cells.The eye is particularly susceptible to oxidative stress due to its prolonged exposure to light and its anatomical characteristics of high metabolism and oxygen consumption.In addi-tion,inflammation,aging,genetic and environmental factors can promote the production of reactive oxygen species and weaken antioxidant defense mechanisms,which are all risk factors for oxidative stress that can lead to a variety of ocular diseases.The aim of this paper is to review the mechanisms of oxidative stress in ocular diseases such as ocular surface diseases,glaucoma,cataract,and retinopathy.At the same time,the potential therapeutic approaches to these diseases by regulating oxidative stress are discussed,so as to provide new ideas and directions for the diagnosis and treatment of ocular diseases.

Objective To investigate the association of insulin resistance(IR)and its related indices,including triacylglycerol-glucose(TyG)index and metabolic score of insulin resistance(Mets-IR),with the occurrence of early neurological deterioration(END)in patients with branch atheromatous disease(BAD),and develop a risk prediction model based on these factors.Methods A total of 189 BAD patients were consecutively recruited from the Department of Neurology of the Second Affiliated Hospital of Zhengzhou University between March 2020 and August 2024.Based on the occurrence of END within 7 d after admission,the participants were stratified into END(75 cases)and non-END(114 cases)groups.Demographic characteristics,clinical parameters,TyG index and Mets-IR values were systematically collected and analyzed.Multivariate logistic regression analysis was performed to identify independent risk factors for END in BAD-related stroke.Receiver operating characteristic curve(ROC)analysis was subsequently conducted to evaluate the predictive performance of significant variables,followed by construction of a nomogram prediction model.Results The END group exhibited significantly elevated fasting blood glucose[6.47(5.74,7.86)mmol/L vs 5.83(5.14,6.70)mmol/L]and triacylglycerol[1.65(1.21,2.04)mmol/L vs 1.27(0.99,1.57)mmol/L]levels,higher body mass index[25.02(23.88,26.67)kg/m2 vs 23.71(22.66,25.27)kg/m2]and TyG index(9.03±0.41 vs 8.71±0.45),and increased Mets-IR(39.98±4.23 vs 36.85±4.38)and NIHSS score[5.00(3.00,7.00)vs 3.00(2.00,5.00)]at admission when compared with the non-END group(P＜0.05).Multivariate logistic regression analysis showed that high TyG index(OR=3.751,95％CI:1.592-9.202,P＜0.01),Mets-IR(OR=1.146,95％CI:1.049-1.252,P＜0.01),and NIHSS score at admission(OR=1.279,95％CI:1.128-1.451,P＜0.01)were risk factors for the occurrence of END in BAD patients(P＜0.05).ROC curve indicated that the AUC value of TyG index,Mets-IR,and NIHSS score at admission in predicting END occurrence was 0.698(95％CI:0.623-0.774,P＜0.01),0.698(95％CI:0.620-0.775,P＜0.01),and 0.666(95％CI:0.586-0.745,P＜0.01),respectively.The nomogram prediction model based on these factors demonstrated significant clinical benefits by decision curve analysis and goodness of fit in internal calibration analysis.Conclusion IR shows significant association with END in BAD patients.The IR related indices,TyG index and Mets-IR,have certain predictive efficiency for occurrence and progression of END.

An 85-year-old male patient received left thyroxine sodium (LT4) 50 μg orally once daily for replacement therapy because of ischemic stroke and hypothyroidism. Next day, laboratory test showed that blood potassium was 3.0 mmol/L. He was given potassium chloride sustained-release tablets 1 g orally thrice daily. Six days later, the patient complained of a rapid heartbeat after slight activity. Laboratory tests showed that blood potassium was 3.3 mmol/L and a potassium magnesium aspartate tablet was administered orally thrice daily. After 8 days of potassium supplementation treatments, the patient's blood potassium level was 3.5 mmol/L, while the blood pressure increased to 163/90 mmHg. Losartan potassium 50 mg once daily was given orally. Clinical pharmacist consulted and learned that the patient continued to take his own LT4 75 μg once daily while following the doctor's instructions to take LT4 50 μg once daily. The patient was instructed to immediately stop taking his own medication and the LT4 dose was adjusted to 75 μg once daily. Thirteen days later, the patient's serum potassium returned to 4.0 mmol/L and no further discomfort occurred.

Objective:To explore and establish a standardized clinical thinking mode and decision-making pathway for lactation medication consultation services and ensure the harmonization and safety of medication for lactating women.Methods:Lactation medication consultation services for medical staffs conducted by pharmacists from June 2020 to August 2022 in Peking University Third Hospital were analyzed using methods of retrospective statistical analysis and root cause analysis. Application of mixed methods were used to establish a clinical thinking model for medication use during lactation and a clinical pathway for safe medication use during lactation. Lactation medication consultation service training for pharmacists was provided, questionnaire surveys before and after the training were conducted, and the effectiveness of improvement was evaluated.Results:A total of 1 218 medication consultation services provided by clinical pharmacists to medical staffs were collected in the hospital, including 44 cases (3.61%) related to lactation medication. Retrospective analysis showed that clinical pharmacists did not have a clear understanding of patients′ needs, incomplete consideration of drug-maternal-infant factors, and a limited way to retrieve information in the lactation medication consultation service. Based on the root cause analysis of the problems, a clinical thinking mode of "Questions (Q), Assessment (A), Search (S), and Plan (P)" (QASP) were established. Additionally, a clinical pathway for safe medication decision-making analysis and a standard medication consultation record template was developed. Compared with before training, clinical pharmacists made significant progress in clarifying factors related to lactation medication, evidence-based procedure, standardized documentation, and confidence in providing medication consulations (all P<0.001). Conclusion:The establishment of the QASP clinical thinking model and decision analysis model, based on the 3 factors of medication, mother, and baby for the consultation service of safe medication during lactation, can help clinical pharmacists carry out standardized medication consultation services for breast-feeding populations during lactation, and improve the quality of homogeneous pharmaceutical services.